Arcturus at Canaccord: Pivoting from COVID Vaccines to Rare Disease Frontiers

SAN DIEGO, CA – July 20, 2026 – When executives from Arcturus Therapeutics take the stage for a fireside chat at the Canaccord Genuity 46th Annual Growth Conference next month, they will face an investment community hungry for a clear vision of the future. The presentation, scheduled for August 11, is more than a routine update; it represents a pivotal moment for the mRNA medicines company as it navigates a strategic pivot from the volatile post-pandemic vaccine market toward the high-value, high-need arena of rare disease therapeutics.

Founded in 2013, Arcturus was a key player in the mRNA revolution, developing KOSTAIVE®, the world's first approved self-amplifying mRNA (sa-mRNA) COVID-19 vaccine. But as the global health landscape evolves, the company is increasingly focusing its powerful STARR® and LUNAR® technology platforms on complex genetic disorders. The upcoming conference offers a prime opportunity for Arcturus to articulate how this strategic shift will unlock long-term value and redefine its position in the competitive biotech landscape.

The Investor Spotlight at Canaccord

The Canaccord Genuity conference is a critical venue for growth-oriented companies to connect with institutional investors, and the timing for Arcturus could not be more significant. The company is expected to report its Q2 2026 earnings on August 10, the day before the fireside chat. This sequencing makes the presentation the first public forum for management to provide color on the latest financial results and answer pressing investor questions, setting a high-stakes tone for the event.

Investors will be parsing the commentary against a mixed financial backdrop. In its first quarter of 2026, Arcturus reported revenue of $2.1 million, a steep decline from the $29.4 million posted in the same period last year, primarily due to lower revenue from its collaboration with CSL Seqirus. The company also posted a net loss of $27.0 million. However, a closer look reveals a strategic reallocation of resources. Operating expenses fell to $31.0 million from $46.2 million year-over-year, driven by reduced spending on COVID-related programs as the company doubles down on its rare disease pipeline. This financial discipline, combined with a projected cash runway extending beyond the second quarter of 2028, provides a stable foundation for its long-term strategy.

Analyst sentiment reflects this transitional phase, with a consensus “Moderate Buy” rating. While some have tempered near-term expectations following the Q1 revenue miss, others maintain high price targets, with some projecting an upside of over 200%, banking on the potential of the company's advanced pipeline. The fireside chat will be a crucial test of management's ability to reinforce that bullish long-term narrative, providing clarity on the commercial path for its rare disease assets and its strategy for sustainable growth.

Beyond Vaccines: A Pipeline Targeting Unmet Needs

The core of Arcturus's long-term value proposition lies in its proprietary technology and its application to diseases with few, if any, treatment options. The company's platform is built on two key innovations: the LUNAR® lipid-mediated delivery system and the STARR® self-amplifying mRNA technology.

Unlike conventional mRNA, STARR® technology enables the mRNA strand to replicate itself inside the cell. This self-amplification means a much smaller initial dose can produce a robust and sustained therapeutic effect. This not only improves the potential safety profile but also streamlines manufacturing. When paired with the LUNAR® delivery vehicle, which is designed to efficiently transport the mRNA payload to target tissues like the lungs or liver, the platform becomes a versatile tool for tackling complex genetic diseases.

Two lead candidates exemplify this strategy:

• ARCT-032 for Cystic Fibrosis (CF): Arcturus is advancing an inhaled mRNA therapeutic for individuals with CF who have Class I mutations. These patients produce no functional CFTR protein and therefore do not benefit from existing CFTR modulator therapies. In early 2026, the company initiated a 12-week Phase 2 study for ARCT-032. Interim data has already shown promising signals of biological activity, including reductions in mucus plugging, offering a glimmer of hope for this underserved population. The program's progress is a central pillar of the company's rare disease strategy.

• ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency: This rare, life-threatening genetic disorder impairs the body's ability to break down ammonia. Arcturus is developing ARCT-810 as an mRNA replacement therapy. Following productive discussions with the FDA, the company now has a clear regulatory path toward a pivotal trial, with a focus on addressing the severe unmet need in newborns and young children. An End-of-Phase 2 meeting is anticipated in the second half of 2026, marking a significant step toward late-stage development.

The Power of Partnerships in a Shifting Landscape

While Arcturus is pivoting, it isn't abandoning its expertise in infectious diseases. However, recent events have highlighted the challenges of the commercial vaccine market. The company’s partner, CSL, recorded a significant write-down related to the COVID vaccine collaboration, citing declining demand and regulatory hurdles in the U.S. This underscores the strategic wisdom of diversifying into rare diseases, where the path to market, pricing power, and patient need are often more clearly defined.

Arcturus's strategy is heavily reinforced by a web of powerful alliances that validate its technology and de-risk its ambitious programs. The collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA) on a pandemic flu vaccine continues, providing non-dilutive funding and government validation of its sa-mRNA platform. In Japan, its joint venture, ARCALIS, provides critical manufacturing capabilities as its partner Meiji prepares KOSTAIVE® for the upcoming season.

Perhaps the most telling recent development is the new strategic collaboration with Thermo Fisher Scientific, announced in early July. This partnership will leverage Thermo Fisher's vast manufacturing and clinical research capabilities to support the Phase 3 development and potential commercialization of the cystic fibrosis candidate, ARCT-032. Securing a partner of this caliber is a major vote of confidence and significantly accelerates the program's path to market by providing world-class operational expertise and scale.

As Arcturus prepares for its moment at Canaccord, it stands as a company in deliberate transition. It is leveraging the lessons and technology honed during the pandemic to build a more durable, long-term business focused on transformative therapies for rare diseases. Investors will be listening intently for confirmation that this strategic pivot, backed by a strong cash position and powerful new alliances, is ready to create lasting value.